PubMed Health⌕ Search

Biomedical subjects

C Mery

Publications and source records attributed to C Mery.

At least 19 recordsLinked to original sources
PubMed1990

[Pain-function indices for the follow-up of osteoarthritis of the hip and the knee].

Algo-functional or severity index for hip diseases (AFIH), proposed in 1980 and validated in 1981, and algo-functional or severity index for knee diseases (AFIK), validated in 1985-1987, were applied to osteo-arthritis of the hip and of the knee. With strictly standardized interviews and well-trained investigators (20 to 30 patients), these indices are reliable: the interobserver reproducibility is good (mean discrepancy: 1/2 point) and the score usually decreases 3 points (mean) under active drug treatment. Each index was individually validated. The severity index for hip is more discriminant than that for knee diseases. The place of each index among the other assessment tests was appraised according to their discriminant capacity. These indices are useful: 1) for drug trials (analgesics and NSAIDs); 2) for the long term follow-up and the so-called chondroprotective agents trials; 3) for a rational decision concerning hip or knee prosthesis (score reaching 8 to 12 points). These AFIH and AFIK are well suited to daily practice and are not time-consuming: 3 to 4 minutes for each.

Cross-Sectional Studies↗
PubMed1988

[Acadione, a new long-term treatment of rheumatoid polyarthritis].

This article summarizes the authors' experience and data from the literature regarding acadione, a medication like D-penicillamine with a thiol radical, in the treatment of rheumatoid arthritis. Two control studies versus placebo and two control trial versus D-penicillamine prove the effectiveness of the treatment and demonstrate a similar activity between 1 g of acadione and 600 mg of D-penicillamine. The side-effects of acadione are similar of those of D-penicillamine, essentially rash, toxic dermatitis, agueusia, proteinuria, which disappear upon discontinuation of the treatment. The fact that the patient exhibited a side effect with D-penicillamine, increases, the risk with acadione, but this is not systematic, which is the main advantage of this product.

Amino Acids, Sulfur↗
PubMed1988

Evaluation of a functional index and an articular index in ankylosing spondylitis.

We describe an index of functional impairment and a system of scoring joint tenderness for use in the assessment of ankylosing spondylitis. The functional index consists of 20 questions and the articular index is based on the scoring of a total of 10 joint responses after movement or firm digital pressure. These indices are simple to establish and not time consuming. They have a high degree of intra- and interobserver reproducibility. The indices showed changes in short term clinical trials of antiinflammatory drugs; these changes were highly correlated with the patient's overall assessment of his own clinical condition.

Activities of Daily Living↗
PubMed1987

Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials.

Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day). Nonathymulin 5 mg proved to be the most efficient dose, providing significant clinical improvement as evaluated by the global assessment of all patients who entered the trials (56% v 17% in the placebo group) (p less than 0.02) and by four objective parameters. This effect was accompanied with minimal adverse effects and was not associated with clear changes in immunological parameters. A significant correlation was observed, however, in clinical response to nonathymulin, and T cell subset imbalance was assessed using monoclonal anti-T cell antibodies and a functional suppressor T cell assay.

Arthritis, Rheumatoid↗
PubMed1987

Indexes of severity for osteoarthritis of the hip and knee. Validation--value in comparison with other assessment tests.

The index for hip disease (ISH) was established, validated and appraised as a new assessment test for the trial of new drugs as well as for long-term follow-up of patients, and to help with future indications for surgery. The ISH deals with pain, maximum walking distance, and some activities of daily living. Inter-observer reproducibility is good (mean deviation 0.55 points; p less than 0.05). In a short-term, double-blind crossover trial, the ISH, judged according to its power to distinguish between the active drug period and the placebo period, appears as one of the best assessment tests. In the long term, total hip prosthesis is most often justified when the ISH score reaches 10-12 points. The index of severity for knee disease (ISK) was validated and appraised by the same statistical methods. Its value in non-steroidal anti-inflammatory drug (NSAID) or analgesic trials is lower than the value of the ISH. However, its use is still justified for that purpose, and for long-term follow-up of osteoarthritis of the knee.

Hip Joint↗
PubMed1986

[Tiopronine and rheumatoid polyarthritis].

This article summarises the authors' experience and the data of the literature concerning Tiopronine, a drug with a thiol function like D-penicillamine, in the treatment of rheumatoid arthritis. Two controlled trials versus placebo and two controlled trials versus D-penicillamine demonstrated the effectiveness of treatment and the identical action of 1 g of Tiopronine and 600 mg of D-penicillamine. The side effects of Tiopronine are very similar to those of D-penicillamine: essentially rash, toxiderma, aguestia, proteinuria, which resolve when treatment is stopped. Patients with a past history of side effects with D-penicillamine have an increased risk of developing side effects with Tiopronine, but this risk is not systematic, which constitutes the principal value of this drug.

Adrenal Cortex Hormones↗
PubMed1985

Treatment of progressive systemic sclerosis using factor XIII.

A double-blind, randomized crossover trial was carried out in 25 patients with progressive systemic sclerosis to compare the effectiveness and tolerability of treatment with Factor XIII with that of placebo. Patients received twice daily intravenous injections of either Factor XIII or placebo for 3 weeks and, after a wash-out period of 6 weeks, were crossed over to the alternative medication for a further 3 weeks. Assessments made by the physician and patients at the end of each treatment period indicated that Factor XIII was significantly better than placebo in improving the cutaneous manifestations of the disease and these opinions were supported by the significant improvement in the function index which was used to assess the degree of motor disability. Both local and general tolerability of Factor XIII treatment was good and there were no adverse reports.

Clinical Trials as Topic↗
PubMed1984

Epithelial reattachment after gingivectomy in the rat.

It is known that an epithelial reattachment occurs a few days after gingivectomy. Depending upon the surgical procedure and the animal species used, different times have been proposed to obtain a complete reattachment. Nevertheless, it is not known whether there is a correlation between the time required and the sequence of morphologic events involved in this process. To investigate this matter, gingivectomies were performed in the maxillary molars of rats. Specimens were taken 1 to 14 days after the operation and processed for light and electron microscopy. The new junctional epithelium appeared at the 5th day, but the earliest signs of reattachment complex formation were evident at the 8th day. Rudimentary hemidesmosomes and lamina lucida appeared in epithelial cells bordering remnants of fibrin. Anchoring filaments that formed between the earliest hemidesmosomes and the subjacent fibrin crossed the lamina lucida. Simultaneously, segments of lamina densa appeared. At the 11th day insertion of tonofilaments into the attachment plaques and insertion of anchoring filaments in the lamina densa were observed. At the 14th day, full development of the reattachment complex was evident.

Animals↗
PubMed1982

Tiopronin (N-[2-mercaptopropionyl] glycin) in rheumatoid arthritis.

Two controlled trials have demonstrated that tiopronin, a new sulfhydryl compound, is active as a slow-acting antirheumatic drug in rheumatoid arthritis. One trial compared 10 patients receiving placebos and 20 receiving tiopronin, 1 gm/day; the second compared two groups of 16 patients who received either placebos or tiopronin, 1.5 gm/day. In addition, 80 patients (56 from the 2 trials plus 24 other patients) were followed up for a long period. Dropout rate for intolerance or inefficacy was comparable to that fund with D-penicillamine. Secondary toxic reactions resembled those of other sulfhydryl compounds.

Adolescent↗
PubMed1981

Effectiveness of levamisole in rheumatoid arthritis: Immune changes and long-term results.

After a double-blind trial of 4 months, 40 patients with RA were treated with 100 mg Levamisole. Clinical results were good or excellent in 50%. The immunological status is not a valuable criterion for the selection of patients apt to respond to Levamisole. A good correlation was found between clinical improvement, reduction of ESR, percentage of immunoblasts, rheumatoid factor titre and the enhancement of lymphoblastic response to polyclonal mitogens. The treatment maintenance rate for efficacy was much lower for Levamisole than for D-penicillamine.

Adult↗
PubMed1980

[Evaluation of the long term effect of antirheumatic drugs with the survey rate method].

In the long term study of antirheumatic drugs, drop out of patients (for failure of effect or side effects) can analysed with "survey rate" methods. Survey rates become in drug tests "treatment continuation rates". With this method D-penicillamine and levamisole have been compared. Penicillamine has better "continuation rate" not because of better tolerance, but because of better long term effectiveness compared with levamisole.

Evaluation Studies as Topic↗
PubMed1980

[The contour of the normal foot. A statistical study].

The authors, thanks to a statistical study on 292 young adults with healthy feet, have established the common occurrence, that has been suspected clinically, of the arched foot in the classical sense of the term. If one makes an exception of the black race where the flat foot is rather frequent, the white population normally has an arched foot (incipiens, of the 1st or 2nd degree) in 58.2 per cent of cases in men, which increases to 78.8 per cent in women. As for the classically " normal " foot which rather deserves the term " intermediary ", it is found in the white race in 1/3 of subjects.

Adult↗